Skip to main navigation Skip to search Skip to main content

Beyond rhetoric in debates about the Ethics of marketing prescription medicines to consumers: The importance of Vulnerability in people, situations, and relationships

Stacy M. Carter, Gabrielle N. Samuel, Ian Kerridge, Richard Day, Rachel A. Ankeny, Christopher F.C. Jordens, Paul Komesaroff

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    This article examines community responses to the marketing of prescription medicines. Historically, debates about such marketing have focused on alleged unscrupulousness of pharmaceutical companies and on the quality of information provided. Six focus groupswere conducted in Sydney, Australia, three with older and threewith younger community members. Analysis examined interactions between group members, the positions participants took up, conflicting arguments, and explanations for variation. Participants argued specifically rather than generally about consumer marketing of medicines. Neither the moral purpose of corporations nor the quality of information in advertisements was particularly important. Instead, pharmaceutical marketing was assessed in relation to vulnerabilities that existed in individual consumers, in doctors, in the contexts of illness, and as a result of medications being potentially dangerous. The critical ethical issue in prescription medicine marketing may be the existence of vulnerabilities and the responsibilities they may generate.We outline three possible policy responses suggested by these participants.

    Original languageEnglish
    Pages (from-to)11-21
    Number of pages11
    JournalAJOB Primary Research
    Volume1
    Issue number1
    DOIs
    Publication statusPublished - 1 Jan 2010

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • Direct-to-consumer advertising
    • Doctor-patient relationship
    • Drug industry marketing
    • DTCA
    • Vulnerability

    Cite this